CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)
(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

ANTI-TUMOR NANODRUG "CISPLATIN MICELLE INJECTION" OBTAINS CLINICAL TRIAL APPROVAL

The board of directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the "Cisplatin Micelle Injection" (the "**Product**") developed by CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.*(石藥集團中奇製藥技術(石家莊)有限公司), a subsidiary of the Company, has obtained clinical trial approval granted by the National Medical Products Administration of the People's Republic of China to conduct clinical trials in China.

Cisplatin is a first-line drug for the treatment of several solid tumors, but its clinical application is limited by its severe adverse effects such as nephrotoxicity and neurotoxicity. The Group independently developed the Product using block copolymer as a carrier to achieve several unique advantages, including: (i) high drug loading capacity of cisplatin; (ii) lower toxic side effects by reduced accumulation of drugs in normal tissues; and (iii) preferential tumor accumulation attributable to the nanoscale size of cisplatin micelle, which is favourable for enhancing the therapeutic index.

The preclinical studies demonstrated that compared with the conventional cisplatin preparation, the Product exhibited prolonged blood circulation time due to the existence in micelle form after administration; the toxic effects in rats and beagles significantly decreased with the same dose level, while the ototoxicity and neurotoxicity significantly reduced with the same or even higher dose level, thus significantly improving the safety window. At the same time, good anti-tumor effect was seen in several animal models of solid tumors.

The clinical indication of this approval is for the treatment of advanced malignant solid tumors. Based on the preclinical study results, the Product provides a promising prospect of demonstrating good efficacy in clinical trials.

The Product is a Class 2 chemical drug in China and currently there is no product of the same type available in the global market. The Group will endeavor to push forward the clinical trials of the Product and strive to launch the Product as soon as possible.

By order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 20 April 2022

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive directors.

** For identification purposes only*